X hits on this document

140 views

0 shares

0 downloads

0 comments

44 / 49

Page 283

Weintraub et al

Syndromes dinsuffisance cardiaque aiguë

283

clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:13321343.

  • 81.

    Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompen- sated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:10211028.

  • 82.

    Fonarow GC, Yancy CW, Heywood JT; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165:14691477.

  • 83.

    Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J, Masip J, Frank Peacock W, Sliwa K, Gayat E, Ilippatos G, Cleland JG, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010;31:832841.

  • 84.

    Guglin M. Reappraisal of the role of diuretics in heart failure. Cardiol Rev. 2009;17:5659.

  • 85.

    Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, OConnor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136141.

  • 86.

    Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, OConnor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:10641069.

  • 87.

    Ahmed A, Husain A, Love TE, Gambassi G, DellItalia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:14311439.

  • 88.

    Jhund PS, McMurray JJ, Davie AP. The acute vascular effects of fruse- mide in heart failure. Br J Clin Pharmacol. 2000;50:913.

  • 89.

    Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:13481353.

  • 90.

    Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dys- function during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138(pt 1):285290.

  • 91.

    Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunc- tion. Circulation. 1999;100:13111315.

  • 92.

    Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599608.

  • 93.

    Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol. 2000;85:11101113.

  • 94.

    Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:1325.

  • 95.

    Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:14181428.

  • 96.

    Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G17G.

  • 97.

    Gheorghiade M, Mebazaa A. Introduction to acute heart failure syndromes. Am J Cardiol. 2005;96:1G4G.

  • 98.

    Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, Vered Z, Kaluski E. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227234.

  • 99.

    Graff L, Orledge J, Radford MJ, Wang Y, Petrillo M, Maag R. Correl- ation of the Agency for Health Care Policy and Research congestive heart failure admission guideline with mortality: peer review organiza- tion voluntary hospital association initiative to decrease events

(PROVIDE) for congestive heart failure. Ann Emerg Med. 1999;34 (pt 1):429437.

  • 100.

    Smith WR, Poses RM, McClish DK, Huber EC, Clemo FL, Alexander D, Schmitt BP. Prognostic judgments and triage decisions for patients with acute congestive heart failure. Chest. 2002;121:16101617.

  • 101.

    Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, OConnor CM, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980988.

  • 102.

    Ambardekar AV, Fonarow GC, Hernandez AF, Pan W, Yancy CW, Krantz MJ; Get With the Guidelines Steering Committee and Hospitals. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines- Heart Failure (GWTG-HF). Am Heart J. 2009;158:644652.

  • 103.

    Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572580.

  • 104.

    Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, OConnor C, Adams KF, Orlandi C, Gheorghiade M. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail. 2007;13:360364.

  • 105.

    Formiga F, Chivite D, Manito N, Casas S, Riera A, Pujol R. Predictors of in-hospital mortality present at admission among patients hospitalised because of decompensated heart failure. Cardiology. 2007;108:7378.

  • 106.

    Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:18141820.

  • 107.

    Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:25812587.

  • 108.

    Auble TE, Hsieh M, Gardner W, Cooper GF, Stone RA, McCausland JB, Yealy DM. A prediction rule to identify low-risk patients with heart failure. Acad Emerg Med. 2005;12:514521.

  • 109.

    Hsieh M, Auble TE, Yealy DM. Validation of the Acute Heart Failure Index. Ann Emerg Med. 2008;51:3744.

  • 110.

    Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007;49:627669.

  • 111.

    Storrow AB, Collins SP, Lyons MS, Wagoner LE, Gibler WB, Lindsell CJ. Emergency department observation of heart failure: preliminary analysis of safety and cost. Congest Heart Fail. 2005;11:6872.

  • 112.

    Peacock WF IV, Albert NM. Observation unit management of heart failure. Emerg Med Clin North Am. 2001;19:209232.

  • 113.

    Peacock WF IV, Remer EE, Aponte J, Moffa DA, Emerman CE, Albert NM. Effective observation unit treatment of decompensated heart failure. Congest Heart Fail. 2002;8:6873.

  • 114.

    Collins S, Schauer D, Gupta A, Brunner H, Storrow A, Eckman M. Cost-effectiveness analysis of ED decision making in non-high-risk heart failure patients. Am J Emerg Med. 2009;27:293302.

  • 115.

    Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685691.

  • 116.

    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327: 669677.

  • 117.

    Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:21942199.

14:01:09:06:11

Page 283

Document info
Document views140
Page views140
Page last viewedThu Dec 08 16:09:14 UTC 2016
Pages49
Paragraphs1916
Words46879

Comments